Outcome of Chronic Daily Headache or Chronic Migraine

Current Pain and Headache Reports

Volumn 20, Issue 1, 2016, Pages 1-10

  Cho, Soo Jin ^a   Song, Tae Jin ^b   Chu, Min Kyung ^a  

^a Hallym University College of Medicine   (South Korea)

^b Ewha Womans University School of Medicine   (South Korea)

Author keywords

Burden; Chronic daily headache; Chronic migraine; Cost; Headache; Quality of life; Treatment

Indexed keywords

AMITRIPTYLINE; ATENOLOL; BOTULINUM TOXIN A; GABAPENTIN; MEMANTINE; PLACEBO; PREGABALIN; TIZANIDINE; TOPIRAMATE; VALPROIC ACID; ZONISAMIDE;

CHRONIC DAILY HEADACHE; COGNITIVE THERAPY; COMORBIDITY; DISEASE ASSOCIATION; DISEASE SEVERITY; ECONOMIC ASPECT; GEOGRAPHIC DISTRIBUTION; HEADACHE ATTRIBUTED LOST TIME INDEX; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HUMAN; LIFESTYLE MODIFICATION; MIDAS (MIGRAINE); NEUROMODULATION; PAIN ASSESSMENT; PRODUCTIVITY; QUALITY OF LIFE; REVIEW; SHORT FORM 36; SOCIAL STATUS; SYSTEMATIC REVIEW; TRANSFORMED MIGRAINE; ANIMAL; HEADACHE; HEADACHE DISORDERS; MIGRAINE DISORDERS; TREATMENT OUTCOME;

ANIMALS; HEADACHE; HEADACHE DISORDERS; HUMANS; MIGRAINE DISORDERS; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 84951027942     PISSN: 15313433     EISSN: 15343081     Source Type: Journal    
DOI: 10.1007/s11916-015-0534-8     Document Type: Review

References (78)

1. Dodick DW. Chronic daily headache. N Engl J Med. 2006;354(2):158–65.
2. Schwedt TJ. Chronic migraine. Br Med J. 2014;348:g1416.
3. Stark RJ, Ravishankar K, Siow HC, Lee KS, Pepperle R, Wang S-J. Chronic migraine and chronic daily headache in the Asia-Pacific region: a systematic review. Cephalalgia. 2013;33(4):266–83.
4. Silberstein SD, Lipton RB. Chronic daily headache. Curr Opin Neurol. 2000;13(3):277–83.
5. Bigal M, Lipton R, Tepper S, Rapoport A, Sheftell F. Primary chronic daily headache and its subtypes in adolescents and adults. Neurology. 2004;63(5):843–7.
6. Lu S, Fuh J, Chen W, Juang K, Wang S. Chronic daily headache in Taipei, Taiwan: prevalence, follow-up and outcome predictors. Cephalalgia. 2001;21(10):980–6.
7. Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edition (beta version). Cephalalgia. 2013;33(9):629–808.
8. Headache Classificaation Subcommittee of the International Headache Society. The international classification of headache disorders: 2nd edition. Cephalalgia. 2004;24 Suppl 1:9–160.
9. Silberstein SD, Lipton RB, Dodick DW. Operational diagnostic criteria for chronic migraine: expert opinion. Headache. 2014;54(7):1258–66.
10. Manack AN, Buse DC, Lipton RB. Chronic migraine: epidemiology and disease burden. Curr Pain Headache Rep. 2011;15(1):70–8.
11. Natoli J, Manack A, Dean B, Butler Q, Turkel C, Stovner L, et al. Global prevalence of chronic migraine: a systematic review. Cephalalgia. 2009;30(5):599–609.
12. Blumenfeld AM, Varon SF, Wilcox TK, Buse DC, Kawata AK, Manack A, et al. Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the International Burden of Migraine Study (IBMS). Cephalalgia. 2011;31(3):301–15. This international web-based cross-sectional study with participants from ten countries shed on the light of the severe disability of chronic migraine.
13. Chong CD, Dodick DW, Schlaggar BL, Schwedt TJ. Atypical age-related cortical thinning in episodic migraine. Cephalalgia. 2014;34(14):1115–24.
14. Leonardi M, Raggi A. Burden of migraine: international perspectives. Neurol Sci. 2013;34 Suppl 1:S117–8.
15. Katsarava Z, Buse DC, Manack AN, Lipton RB. Defining the differences between episodic migraine and chronic migraine. Curr Pain Headache Rep. 2012;16(1):86–92.
16. Steiner TJ, Stovner LJ, Birbeck GL. Migraine: the seventh disabler. J Headache Pain. 2013;14:1.
17. Lanteri-Minet M, Duru G, Mudge M, Cottrell S. Quality of life impairment, disability and economic burden associated with chronic daily headache, focusing on chronic migraine with or without medication overuse: a systematic review. Cephalalgia. 2011;31(7):837–50. This article showed extensive reviews of quality of life, disability, and economic burden of chronic daily headache or chronic migraine with elegant figure and tables.
18. Bigal ME, Rapoport AM, Lipton RB, Tepper SJ, Sheftell FD. Assessment of migraine disability using the migraine disability assessment (MIDAS) questionnaire: a comparison of chronic migraine with episodic migraine. Headache. 2003;43(4):336–42.
19. Steiner TJ, Paemeleire K, Jensen R, Valade D, Savi L, Lainez MJ, et al. European principles of management of common headache disorders in primary care. J Headache Pain. 2007;8 Suppl 1:S3–47.
20. Fiane I, Haugland ME, Stovner LJ, Zwart JA, Bovim G, Hagen K. Sick leave is related to frequencies of migraine and non-migrainous headache—the HUNT Study. Cephalalgia. 2006;26(8):960–7.
21. Bigal ME, Serrano D, Reed M, Lipton RB. Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment. Neurology. 2008;71(8):559–66.
22. Lanteri-Minet M, Auray JP, El Hasnaoui A, Dartigues JF, Duru G, Henry P, et al. Prevalence and description of chronic daily headache in the general population in France. Pain. 2003;102(1–2):143–9.
23. D’Amico D, Grazzi L, Usai S, Rigamonti A, Curone M, Bussone G. Disability pattern in chronic migraine with medication overuse: a comparison with migraine without aura. Headache. 2005;45(5):553–60.
24. Lanteri-Minet M. Economic burden and costs of chronic migraine. Curr Pain Headache Rep. 2014;18(1):1–6. An updated review on economic burden and costs of chronic migraine.
25. Carod-Artal FJ. Tackling chronic migraine: current perspectives. J Pain Res. 2014;7:185–94.
26. Bussone G, Usai S, Grazzi L, Rigamonti A, Solari A, D’Amico D. Disability and quality of life in different primary headaches: results from Italian studies. Neurol Sci. 2004;25 Suppl 3:S105–7.
27. Yu S, Liu R, Zhao G, Yang X, Qiao X, Feng J, et al. The prevalence and burden of primary headaches in China: a population-based door-to-door survey. Headache. 2012;52(4):582–91.
28. Queiroz LP, Silva Junior AA. The prevalence and impact of headache in Brazil. Headache. 2015;55 Suppl 1:32–8.
29. Zebenholzer K, Andree C, Lechner A, Broessner G, Lampl C, Luthringshausen G, et al. Prevalence, management and burden of episodic and chronic headaches—a cross-sectional multicentre study in eight Austrian headache centres. J Headache Pain. 2015;16(1):531.
30. D’Amico D, Usai S, Grazzi L, Rigamonti A, Solari A, Leone M, et al. Quality of life and disability in primary chronic daily headaches. Neurol Sci. 2003;24 Suppl 2:S97–100.
31. Buse DC, Manack AN, Fanning KM, Serrano D, Reed ML, Turkel CC, et al. Chronic migraine prevalence, disability, and sociodemographic factors: results from the American Migraine Prevalence and Prevention Study. Headache. 2012;52(10):1456–70.
32. Abu Bakar N, Tanprawate S, Lambru G, Torkamani M, Jahanshahi M, Matharu M. Quality of life in primary headache disorders: a review. Cephalalgia. 2015:0333102415580099. Recent update of quality of life of migraine, tension-type headache, and chronic daily headache focusing with detailed description of assessing instrument and study quality.
33. Adams AM, Serrano D, Buse DC, Reed ML, Marske V, Fanning KM, et al. The impact of chronic migraine: The Chronic Migraine Epidemiology and Outcomes (CaMEO) Study methods and baseline results. Cephalalgia. 2015;35(7):563–78.
34. Bagley CL, Rendas-Baum R, Maglinte GA, Yang M, Varon SF, Lee J, et al. Validating Migraine-Specific Quality of Life Questionnaire v2.1 in episodic and chronic migraine. Headache. 2012;52(3):409–21.
35. da Rocha NS, Power MJ, Bushnell DM, Fleck MP. The EUROHIS-QOL 8-item index: comparative psychometric properties to its parent WHOQOL-BREF. Value Health. 2012;15(3):449–57.
36. Ware Jr JE, Sherbourne CD, The MOS. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473–83.
37. Duru G, Auray JP, Gaudin AF, Dartigues JF, Henry P, Lanteri-Minet M, et al. Impact of headache on quality of life in a general population survey in France (GRIM2000 Study). Headache. 2004;44(6):571–80.
38. Barton-Donovan K, Blanchard EB. Psychosocial aspects of chronic daily headache. J Headache Pain. 2005;6(1):30–9.
39. Guitera V, Munoz P, Castillo J, Pascual J. Quality of life in chronic daily headache: a study in a general population. Neurology. 2002;58(7):1062–5.
40. Meletiche DM, Lofland JH, Young WB. Quality-of-life differences between patients with episodic and transformed migraine. Headache. 2001;41(6):573–8.
41. Wang SJ, Fuh JL, Lu SR, Juang KD. Quality of life differs among headache diagnoses: analysis of SF-36 survey in 901 headache patients. Pain. 2001;89(2–3):285–92.
42. Coeytaux RR, Spierings EL. Prognostic factors, disability, and functional status among patients in a headache specialty practice. Cephalalgia. 2006;26(1):7–13. doi:10.1111/j.1468-2982.2005.00976.x.
43. Manzoni GC, Torelli P. Epidemiological classification and social impact of chronic headache. Intern Emerg Med. 2010;5 Suppl 1:S1–5.
44. Cavallini A, Micieli G, Bussone G, Rossi F, Nappi G. Headache and quality of life. Headache. 1995;35(1):29–35.
45. Steiner TJ, Birbeck GL, Jensen R, Katsarava Z, Martelletti P, Stovner LJ. The global campaign, world health organization and lifting the burden: collaboration in action. J Headache Pain. 2011;12(3):273–4.
46. Steiner TJ, Gururaj G, Andree C, Katsarava Z, Ayzenberg I, Yu SY, et al. Diagnosis, prevalence estimation and burden measurement in population surveys of headache: presenting the HARDSHIP questionnaire. J Headache Pain. 2014;15:3.
47. Buse DC, Manack A, Serrano D, Turkel C, Lipton RB. Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers. J Neurol Neurosurg Psychiatry. 2010;81(4):428–32.
48. Lipton R, Scher A, Steiner T, Bigal M, Kolodner K, Liberman J, et al. Patterns of health care utilization for migraine in England and in the United States. Neurology. 2003;60(3):441–8.
49. Sanderson JC, Devine EB, Lipton RB, Bloudek LM, Varon SF, Blumenfeld AM, et al. Headache-related health resource utilisation in chronic and episodic migraine across six countries. J Neurol Neurosurg Psychiatry. 2013;84(12):1309–17.
50. Munakata J, Hazard E, Serrano D, Klingman D, Rupnow MF, Tierce J, et al. Economic burden of transformed migraine: results from the American Migraine Prevalence and Prevention (AMPP) Study. Headache. 2009;49(4):498–508.
51. Wang SJ, Wang PJ, Fuh JL, Peng KP, Ng K. Comparisons of disability, quality of life, and resource use between chronic and episodic migraineurs: a clinic-based study in Taiwan. Cephalalgia. 2013;33(3):171–81.
52. Park JW, Moon HS, Kim JM, Lee KS, Chu MK. Chronic daily headache in Korea: prevalence, clinical characteristics, medical consultation and management. J Clin Neurol. 2014;10(3):236–43.
53. Stewart WF, Wood GC, Manack A, Varon SF, Buse DC, Lipton RB. Employment and work impact of chronic migraine and episodic migraine. J Occup Environ Med. 2010;52(1):8–14.
54. Lionetto L, Negro A, Palmisani S, Gentile G, Fiore MRD, Mercieri M, et al. Emerging treatment for chronic migraine and refractory chronic migraine. Expert Opin Emerg Drugs. 2012;17(3):393–406.
55. Mulleners WM, McCrory DC, Linde M. Antiepileptics in migraine prophylaxis: an updated Cochrane review. Cephalalgia. 2015;35(1):51–62. A concise and updated review of migraine and chronic migraine prophylaxis.
56. Bigal M, Rapoport A, Sheftell F, Tepper D, Tepper S. Memantine in the preventive treatment of refractory migraine. Headache. 2008;48(9):1337–42.
57. Calandre EP, Garcia-Leiva JM, Rico-Villademoros F, Vilchez JS, Rodriguez-Lopez CM. Pregabalin in the treatment of chronic migraine: an open-label study. Clin Neuropharmacol. 2010;33(1):35–9.
58. Edvardsson B. Atenolol in the prophylaxis of chronic migraine: a 3-month open-label study. Springer Plus. 2013;2(1):479.
59. Magalhães E, Menezes C, Cardeal M, Melo A. Botulinum toxin type A versus amitriptyline for the treatment of chronic daily migraine. Clin Neurol Neurosurg. 2010;112(6):463–6.
60. Pascual-Gómez J, Alañá-García M, Oterino A, Leira R, Láinez-Andrés J. Preventive treatment of chronic migraine with zonisamide: a study in patients who are refractory or intolerant to topiramate. Rev Neurol. 2007;47(9):449–51.
61. Saper JR, Lake AE, Cantrell DT, Winner PK, White JR. Chronic daily headache prophylaxis with tizanidine: a double‐blind, placebo‐controlled, multicenter outcome study. Headache. 2002;42(6):470–82.
62. Yurekli VA, Akhan G, Kutluhan S, Uzar E, Koyuncuoglu HR, Gultekin F. The effect of sodium valproate on chronic daily headache and its subgroups. J Headache Pain. 2008;9(1):37–41.
63. Pistoia F, Sacco S, Carolei A. Behavioral therapy for chronic migraine. Curr Pain Headache Rep. 2013;17(1):1–8.
64. Reed K, Black S, Banta C, Will K. Combined occipital and supraorbital neurostimulation for the treatment of chronic migraine headaches: initial experience. Cephalalgia. 2009;30(3):260–71.
65. Yang C, Chang M, Liu P, Li T, Hsieh C, Hwang K, et al. Acupuncture versus topiramate in chronic migraine prophylaxis: a randomized clinical trial. Cephalalgia. 2011;31(15):1510–21.
66. Diener H, Bussone G, Van Oene J, Lahaye M, Schwalen S, Goadsby P. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia. 2007;27(7):814–23.
67. Silberstein SD, Lipton RB, Dodick DW, Freitag FG, Ramadan N, Mathew N, et al. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double‐blind, placebo‐controlled trial. Headache. 2007;47(2):170–80.
68. Brandes JL, Saper JR, Diamond M, Couch JR, Lewis DW, Schmitt J, et al. Topiramate for migraine prevention: a randomized controlled trial. JAMA. 2004;291(8):965–73.
69. Storey J, Calder C, Hart D, Potter D. Topiramate in migraine prevention: a double‐blind, placebo‐controlled study. Headache. 2001;41(10):968–75.
70. Aurora S, Dodick D, Turkel C, DeGryse R, Silberstein S, Lipton R, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010;30(7):793–803.
71. Diener H, Dodick D, Aurora S, Turkel C, DeGryse R, Lipton R, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010;30(7):804–14.
72. Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double‐blind, randomized, placebo‐controlled phases of the PREEMPT clinical program. Headache. 2010;50(6):921–36.
73. Naumann M, So Y, Argoff C, Childers M, Dykstra D, Gronseth G, et al. Assessment: botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review) Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008;70(19):1707–14.
74. Spira PJ, Beran RG. Gabapentin in the prophylaxis of chronic daily headache: a randomized, placebo-controlled study. Neurology. 2003;61(12):1753–9.
75. Schulman EA, Lee Peterlin B, Lake AE, Lipton RB, Hanlon A, Siegel S, et al. Defining refractory migraine: results of the RHSIS Survey of American Headache Society members. Headache. 2009;49(4):509–18.
76. Irimia P, Palma J-A, Fernandez-Torron R, Martinez-Vila E. Refractory migraine in a headache clinic population. BMC Neurol. 2011;11(1):94.
77. Dodick DW, Silberstein SD, Reed KL, Deer TR, Slavin KV, Huh B, et al. Safety and efficacy of peripheral nerve stimulation of the occipital nerves for the management of chronic migraine: long-term results from a randomized, multicenter, double-blinded, controlled study. Cephalalgia. 2014;35(4):344–58.
78. DaSilva AF, Mendonca ME, Zaghi S, Lopes M, DosSantos MF, Spierings EL, et al. tDCS‐Induced analgesia and electrical fields in pain‐related neural networks in chronic migraine. Headache. 2012;52(8):1283–95.